Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
100 µCi HMPL-306 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| 100 µCi [14C] HMPL-306 | DRUG | D1: 250 mg/100 µCi \[14C\] HMPL-306 Single dose |
100 µCi HMPL-306 is used in a mass balance study, which is a clinical trial designed to track how a drug is absorbed, distributed, metabolized, and excreted in the body. This specific study is being conducted in healthy Chinese adult male subjects to evaluate the mass balance of [14C]HMPL-306.
100 µCi HMPL-306 is a radiolabeled form of HMPL-306, which is described as an isocitrate dehydrogenase inhibitor. The study title indicates that [14C]HMPL-306 is an isocitrate dehydrogenase inhibitor, meaning it targets isocitrate dehydrogenase enzymes.
100 µCi HMPL-306 is being developed by HUTCHMED (China) Limited, a biopharmaceutical company. The company's ticker symbol is HCM.
100 µCi HMPL-306 is in Phase 1 clinical development. The single clinical trial for this drug is a Phase 1 study that has been completed. It is an investigational drug and is not yet approved for any medical use.
100 µCi HMPL-306 has one completed clinical trial, identified as NCT06671873. This trial is titled "Study on Mass Balance of [14C]HMPL-306（Isocitrate Dehydrogenase Inhibitor） in Healthy Chinese Adult Male Subjects" and enrolled 6 participants.
100 µCi HMPL-306 is a radiolabeled version of HMPL-306, specifically labeled with carbon-14 ([14C]). It is used in a mass balance study to track the drug's behavior in the body. The study title refers to [14C]HMPL-306, indicating it is the same compound with a radioactive label.